يعرض 1 - 7 نتائج من 7 نتيجة بحث عن 'Juha P. Himanen (14851154)', وقت الاستعلام: 0.01s تنقيح النتائج
  1. 1
    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy حسب Amr El Zawily (14851115)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy حسب Amr El Zawily (14851115)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy حسب Amr El Zawily (14851115)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy حسب Amr El Zawily (14851115)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy حسب Amr El Zawily (14851115)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy حسب Amr El Zawily (14851115)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy حسب Amr El Zawily (14851115)

    منشور في 2025
    مؤلفون آخرون:
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: